Alpha Teknova (TKNO) Stock Price, News & Analysis

Company Overview

Alpha Teknova, Inc. develops and manufactures critical reagents and process solutions used in life sciences research, biopharmaceutical production, cell and gene therapies, vaccines, and molecular diagnostics. The company serves customers that require specialized materials for developing, scaling, and commercializing biological products.

Its product portfolio includes research-grade and current good manufacturing practice (cGMP) buffers, reagents, media, and other process fluids. Alpha Teknova also provides custom formulation, development, manufacturing, and packaging services designed to support applications ranging from laboratory research to regulated commercial production.

Founded in 1996 and headquartered in Hollister, California, Alpha Teknova serves biotechnology, pharmaceutical, diagnostic, academic, and research customers. The company supports both off-the-shelf and customized workflows, with an emphasis on supplying the materials needed for reproducible and scalable bioprocessing.

Key Stats

• Today's Range: $8.80 to $9.04
• 50-Day Range: $4.85 to $9.33
• 52-Week Range: $1.91 to $9.48
• Volume: 248,759 shs
• Average Volume: 257,741 shs
• Market Capitalization: $481.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Alpha Teknova Stock Analysis - MarketRank™

Alpha Teknova scored higher than 27% of companies evaluated by MarketBeat, and ranked 755th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Alpha Teknova has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Downside Risk

Alpha Teknova has a consensus price target of $8.00, representing about 11.0% downside from its current price of $8.99.

Amount of Analyst Coverage

Alpha Teknova has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Teknova are expected to grow in the coming year, from ($0.28) to ($0.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Teknova is -29.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Teknova is -29.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Teknova has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.39% of the float of Alpha Teknova has been sold short.

Short Interest Ratio / Days to Cover

Alpha Teknova has a short interest ratio ("days to cover") of 10.83, which indicates bearish sentiment.

Change versus previous month

Short interest in Alpha Teknova has recently increased by 1.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Teknova does not currently pay a dividend.

Dividend Growth

Alpha Teknova does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.66

News Sentiment

Alpha Teknova has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Alpha Teknova this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TKNO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alpha Teknova to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Teknova insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.20% of the stock of Alpha Teknova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.81% of the stock of Alpha Teknova is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TKNO
• CIK: 1850902
• Web: www.teknova.com
• Phone: 831-637-1100
• Fax: N/A
• Employees: 158
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Alpha Teknova: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: -11.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.26 million
• Net Margins: -38.37%
• Pretax Margin: -38.16%
• Return on Equity: -24.94%
• Return on Assets: -16.53%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 4.49
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $40.52 million
• Price / Sales: 11.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.28 per share
• Price / Book: 7.02

Miscellaneous

• Outstanding Shares: 53,610,000
• Free Float: 46,537,000
• Market Cap: $481.95 million
• Optionable: Not Optionable
• Beta: 0.85